Lartesertib (M4076) clinical trials

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

This study is for women with ovarian cancer that has come back after treatment with certain drugs (PARP inhibitors). It's looking at new combinations of medicines (tuvusertib with niraparib or lartesertib) to see how well they work and if they are safe.